Clinical trial · Interventional
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)
NCT04903197CI-TRIAL-00107027terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business decision and not due to any safety or tolerability concerns.
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| lenalidomide | Drug | Lenalidomide | ALIAS |
| VAY736 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Arm 1A
- description
- VAY736 single agent dose escalation in patients with NHL subtypes of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)
- interventionNames
- Drug: VAY736
- type
- EXPERIMENTAL
- label
- Arm 1B
- description
- VAY736 single agent dose expansion in patients with DLBCL. This arm was not conducted.
- interventionNames
- Drug: VAY736
- type
- EXPERIMENTAL
- label
- Arm 2A
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with confirmed diagnosis of relapsed/refractory B-cell NHL with all subtypes of DLBCL, follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) per WHO 2016 criteria. Patients in subtype arm e.g. DLBCL must have confirmed diagnosis of relapsed/refractory DLBCL. * Received and failed or be intolerant to standard of care therapy (at least two prior lines, including an anti-CD20 therapy for NHL) * Must have measurable disease and ECOG of 0 to 2 Exclusion Criteria: * Baseline laboratory results outside of protocol defined ranges * Patients with primary CNS lymphoma * History of hypersensitivity to VAY736 or any drugs in similar chemical classes (e.g. monoclonal antibodies) * Impaired cardiac function or clinically significant cardiac disease * History of or current interstitial lung disease or pneumonitis grade 2 or higher * HIV infection * Active hepatitis C infection and/or hepatitis B infection * Pregnant or nursing (lactating) women * Women of child-bearing potential unless they are using highly effective methods of contraception Other Inclusion/Exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.